ReviewVaccine2008
Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development.
Review in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection.Frontiers in immunology · 2021Trial
- Mechanisms of antibody-dependent enhancement and its research progress in animal coronaviruses.Veterinary research · 2026Review
- Vaccination With a Gamma Irradiation-Inactivated African Swine Fever Virus Is Safe But Does Not Protect Against a Challenge.Frontiers in immunology · 2022Article
- Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.Microbial cell factories · 2021Review
- Antibodies at work in the time of severe acute respiratory syndrome coronavirus 2.Cytotherapy · 2021Review
- Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19.BMC medicine · 2021Article
- AI Aided Design of Epitope-Based Vaccine for the Induction of Cellular Immune Responses Against SARS-CoV-2.Frontiers in genetics · 2021Article
- COVID-19: Structural predictions of viral success.International journal of clinical practice · 2020Article
- Potential benefits, mechanisms, and uncertainties of convalescent plasma therapy for COVID-19.Blood science (Baltimore, Md.) · 2020Review
- Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.Journal of virology · 2020Article
- Article
- Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.Gene therapy · 2015Article
- Monoclonal antibody-based candidate therapeutics against HIV type 1.AIDS research and human retroviruses · 2012Review
- Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.Journal of virology · 2012Article
- On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity.Advances in bioinformatics · 2012Article
- Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli.Infection and immunity · 2011Article
- Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.Retrovirology · 2011Article
- Foot-and-mouth disease virus exhibits an altered tropism in the presence of specific immunoglobulins, enabling productive infection and killing of dendritic cells.Journal of virology · 2011Article
- A novel approach to inhibit HIV-1 infection and enhance lysis of HIV by a targeted activator of complement.Virology journal · 2009Article
- Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.Expert opinion on biological therapy · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering recent HIV vaccine failures, the authors believe that it would be most important to find new targets for vaccine-induced immunity, and to analyze the data from previous trials, using an innovative approach. In their review article, the authors briefly summarize the significance of the antibody-dependent enhancement of infection in different viral diseases and discuss role of these types of antibodies as the obstacles for vaccine development. Findings which indicate that complement-mediated antibody-dependent enhancement (C-ADE) is present also in HIV-infected patients, are summarized. Previous results of the authors, suggesting that C-ADE plays a very important role in the progression of HIV infection are described. Data reflecting that enhancing antibodies may develop even in vaccinated animals and human volunteers, and may be responsible for the paradoxical results obtained in some subgroups of vaccinees are discussed. Finally, based on their hypothesis, the authors offer some suggestions for the future development of vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.